Compare · ABBV vs AVTX
ABBV vs AVTX
Side-by-side comparison of AbbVie Inc. (ABBV) and Avalo Therapeutics Inc. (AVTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and AVTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $500.94B, about 788.9x AVTX ($635.0M).
- Over the past year, ABBV is up 25.8% and AVTX is down 19.5% - ABBV leads by 45.3 points.
- ABBV has been more active in the news (19 items in the past 4 weeks vs 5 for AVTX).
- ABBV has more recent analyst coverage (25 ratings vs 20 for AVTX).
- Company
- AbbVie Inc.
- Avalo Therapeutics Inc.
- Price
- $285.46+0.75%
- $11.27-6.20%
- Market cap
- $500.94B
- $635.0M
- 1M return
- +8.10%
- -32.43%
- 1Y return
- +25.84%
- -19.50%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2015
- News (4w)
- 19
- 5
- Recent ratings
- 25
- 20
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Latest ABBV
- SEC Form 8-K filed by AbbVie Inc.
- AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease
- New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
- AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
- SEC Form 8-K filed by AbbVie Inc.
- SEC Form 4 filed by Director Rapp Edward J
- SEC Form 4 filed by Director Quaggin Susan E
- AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo
- AbbVie to Host Third-Quarter 2026 Earnings Conference Call
- FDA Approval for JUVMO issued to ABBVIE INC
Latest AVTX
- SEC Form 4 filed by Director Lind Kevin Robert
- SEC Form 4 filed by Director Jain Rita
- SEC Form 4 filed by Director Philip Ron M
- Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
- Chief Financial Officer Sullivan Christopher Ryan exercised 12,394 shares at a strike of $9.88 and sold $202,437 worth of shares (12,394 units at $16.33) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Sullivan Christopher Ryan exercised 10,185 shares at a strike of $8.04 and sold $179,457 worth of shares (10,185 units at $17.62) as part of a pre-agreed trading plan (SEC Form 4)
- Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- Avalo Therapeutics to Participate in Upcoming Investor Conferences
- Chief Medical Officer Doyle Mittie exercised 679 shares at a strike of $8.04 and sold $13,580 worth of shares (679 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)